Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Paller CJ, et al. Among authors: leblanc ml. Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Clin Cancer Res. 2014. PMID: 25125258 Free PMC article. Review.
Randomized phase II designs.
Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Rubinstein L, et al. Clin Cancer Res. 2009 Mar 15;15(6):1883-90. doi: 10.1158/1078-0432.CCR-08-2031. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276275 Free PMC article. Review.
Multiple Histology Phase II Trials.
Leblanc M, Rankin C, Crowley J. Leblanc M, et al. Clin Cancer Res. 2009 Jul 1;15(13):4256-62. doi: 10.1158/1078-0432.CCR-08-2069. Epub 2009 Jun 23. Clin Cancer Res. 2009. PMID: 19549777
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. Seymour L, et al. Clin Cancer Res. 2010 Mar 15;16(6):1764-9. doi: 10.1158/1078-0432.CCR-09-3287. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215557 Free PMC article.
Development and use of integral assays in clinical trials.
Schilsky RL, Doroshow JH, Leblanc M, Conley BA. Schilsky RL, et al. Clin Cancer Res. 2012 Mar 15;18(6):1540-6. doi: 10.1158/1078-0432.CCR-11-2202. Clin Cancer Res. 2012. PMID: 22422406 Free PMC article.
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Press OW, et al. Clin Cancer Res. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15. Clin Cancer Res. 2013. PMID: 24130072 Free PMC article.
137 results